adherium

Company Snapshot

Founded: 2001

Entity Type: Public

Region: Europe

Revenue: $551.2 Millions

Revenue Year: 2023

Headquarter: Australia

Key Geographics: North America, Europe, New Zealand, Australia

Company Overview

Incorporated in 2001, Adherium designs, develops, manufactures and supplies digital health technologies for the management of chronic diseases. It offers Smartinhaler, a medical device for prescription respiratory medications. Nexus6 received FDA clearance for its smartphone-connected inhaler. The new SmartTouch device has been cleared as a prescribable metered dose inhaler with a limited number of clinical uses.

adherium In Reports

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

BCC Research Market Report for Chronic Disease Management. Global Chronic Disease Management market trends, with CAGRs through 2026.

Medication Adherence: Systems, Technologies and Global Markets

According to BCC Research global market for medication adherence systems and technologies should grow from $3.5 billion in 2020 to $6.0 billion by 2025 with a compound annual growth rate (CAGR) of 11.4%.

OTC Drugs, Medical Devices and Diagnostics: Global Markets

Get an overview of the global markets for over-the-counter (OTC) drugs, medical devices and diagnostics. Analyses of global market trends with data from 2018 to 2019, and projections of compound annual growth rates...

View All Reports

adherium

Company Snapshot

Company Overview

adherium In Reports

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

Medication Adherence: Systems, Technologies and Global Markets

OTC Drugs, Medical Devices and Diagnostics: Global Markets

adherium In News

Adherium Limited Announces Director’s Interest Changes - TipRanks

Adherium pushes ahead with US expansion and stronger commercial focus - Biotech Dispatch

Adherium Addresses Late Lodgement of Appendices 3Y - TipRanks

Smartinhaler ensures effective asthma treatment when it’s needed - New Atlas